These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 10941827)

  • 1. Cytotoxic T-lymphocyte responses elicited to Wilms' tumor gene WT1 product by DNA vaccination.
    Tsuboi A; Oka Y; Ogawa H; Elisseeva OA; Li H; Kawasaki K; Aozasa K; Kishimoto T; Udaka K; Sugiyama H
    J Clin Immunol; 2000 May; 20(3):195-202. PubMed ID: 10941827
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Oka Y; Udaka K; Tsuboi A; Elisseeva OA; Ogawa H; Aozasa K; Kishimoto T; Sugiyama H
    J Immunol; 2000 Feb; 164(4):1873-80. PubMed ID: 10657636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human cytotoxic T-lymphocyte responses specific for peptides of the wild-type Wilms' tumor gene (WT1 ) product.
    Oka Y; Elisseeva OA; Tsuboi A; Ogawa H; Tamaki H; Li H; Oji Y; Kim EH; Soma T; Asada M; Ueda K; Maruya E; Saji H; Kishimoto T; Udaka K; Sugiyama H
    Immunogenetics; 2000 Feb; 51(2):99-107. PubMed ID: 10663572
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Human cytotoxic T lymphocyte responses specific to the DNA vaccine of Wilms' tumor gene product].
    Zhang B; Wang Z
    Nan Fang Yi Ke Da Xue Xue Bao; 2009 Jul; 29(7):1348-50. PubMed ID: 19620050
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DNA vaccination induces WT1-specific T-cell responses with potential clinical relevance.
    Chaise C; Buchan SL; Rice J; Marquet J; Rouard H; Kuentz M; Vittes GE; Molinier-Frenkel V; Farcet JP; Stauss HJ; Delfau-Larue MH; Stevenson FK
    Blood; 2008 Oct; 112(7):2956-64. PubMed ID: 18502835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunity to WT1 in the animal model and in patients with acute myeloid leukemia.
    Gaiger A; Reese V; Disis ML; Cheever MA
    Blood; 2000 Aug; 96(4):1480-9. PubMed ID: 10942395
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Simultaneous immunisation with a Wilms' tumour 1 epitope and its ubiquitin fusions results in enhanced cell mediated immunity and tumour rejection in C57BL/6 mice.
    Eslami NS; Shokrgozar MA; Mousavi A; Azadmanesh K; Nomani A; Apostolopoulos V; Day S; Amanzadeh A; Alimohammadian MH
    Mol Immunol; 2012 Jul; 51(3-4):325-31. PubMed ID: 22525006
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide.
    Ohminami H; Yasukawa M; Fujita S
    Blood; 2000 Jan; 95(1):286-93. PubMed ID: 10607714
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification and characterization of a WT1 (Wilms Tumor Gene) protein-derived HLA-DRB1*0405-restricted 16-mer helper peptide that promotes the induction and activation of WT1-specific cytotoxic T lymphocytes.
    Fujiki F; Oka Y; Tsuboi A; Kawakami M; Kawakatsu M; Nakajima H; Elisseeva OA; Harada Y; Ito K; Li Z; Tatsumi N; Sakaguchi N; Fujioka T; Masuda T; Yasukawa M; Udaka K; Kawase I; Oji Y; Sugiyama H
    J Immunother; 2007 Apr; 30(3):282-93. PubMed ID: 17414319
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Induction of WT1 (Wilms' tumor gene)-specific cytotoxic T lymphocytes by WT1 peptide vaccine and the resultant cancer regression.
    Oka Y; Tsuboi A; Taguchi T; Osaki T; Kyo T; Nakajima H; Elisseeva OA; Oji Y; Kawakami M; Ikegame K; Hosen N; Yoshihara S; Wu F; Fujiki F; Murakami M; Masuda T; Nishida S; Shirakata T; Nakatsuka S; Sasaki A; Udaka K; Dohy H; Aozasa K; Noguchi S; Kawase I; Sugiyama H
    Proc Natl Acad Sci U S A; 2004 Sep; 101(38):13885-90. PubMed ID: 15365188
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Wilms' tumor gene WT1: its oncogenic function and clinical application.
    Sugiyama H
    Int J Hematol; 2001 Feb; 73(2):177-87. PubMed ID: 11372729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. WT1 as a novel target antigen for cancer immunotherapy.
    Oka Y; Tsuboi A; Elisseeva OA; Udaka K; Sugiyama H
    Curr Cancer Drug Targets; 2002 Mar; 2(1):45-54. PubMed ID: 12188920
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Elimination of leukemic CD34+ progenitor cells by using cytotoxic T lymphocytes specifically targeting WT1-derived peptide: an experimental study in vitro].
    Gu WY; Chen ZX; Qiu GQ; Hu SY; Jia L; Wu W; He J; Cen JN; He B
    Zhonghua Yi Xue Za Zhi; 2008 Dec; 88(48):3401-6. PubMed ID: 19159569
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of WT1 peptide cancer vaccine against hematopoietic malignancies and solid cancers.
    Oka Y; Tsuboi A; Kawakami M; Elisseeva OA; Nakajima H; Udaka K; Kawase I; Oji Y; Sugiyama H
    Curr Med Chem; 2006; 13(20):2345-52. PubMed ID: 16918359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DNA vaccination primes MHC class I-restricted, simian virus 40 large tumor antigen-specific CTL in H-2d mice that reject syngeneic tumors.
    Schirmbeck R; Böhm W; Reimann J
    J Immunol; 1996 Oct; 157(8):3550-8. PubMed ID: 8871655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine.
    Osada T; Woo CY; McKinney M; Yang XY; Lei G; Labreche HG; Hartman ZC; Niedzwiecki D; Chao N; Amalfitano A; Morse MA; Lyerly HK; Clay TM
    Clin Cancer Res; 2009 Apr; 15(8):2789-96. PubMed ID: 19351755
    [TBL] [Abstract][Full Text] [Related]  

  • 17. WT1 peptide vaccine for the treatment of cancer.
    Oka Y; Tsuboi A; Oji Y; Kawase I; Sugiyama H
    Curr Opin Immunol; 2008 Apr; 20(2):211-20. PubMed ID: 18502632
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer immunotherapy targeting Wilms' tumor gene WT1 product.
    Sugiyama H
    Expert Rev Vaccines; 2005 Aug; 4(4):503-12. PubMed ID: 16117707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced tumor immunity of WT1 peptide vaccination by interferon-β administration.
    Nakajima H; Oka Y; Tsuboi A; Tatsumi N; Yamamoto Y; Fujiki F; Li Z; Murao A; Morimoto S; Hosen N; Shirakata T; Nishida S; Kawase I; Isaka Y; Oji Y; Sugiyama H
    Vaccine; 2012 Jan; 30(4):722-9. PubMed ID: 22133512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a WT1 protein-derived peptide, WT1, as a HLA-A 0206-restricted, WT1-specific CTL epitope.
    Li Z; Oka Y; Tsuboi A; Fujiki F; Harada Y; Nakajima H; Masuda T; Fukuda Y; Kawakatsu M; Morimoto S; Katagiri T; Tatsumi N; Hosen N; Shirakata T; Nishida S; Kawakami Y; Udaka K; Kawase I; Oji Y; Sugiyama H
    Microbiol Immunol; 2008 Nov; 52(11):551-8. PubMed ID: 19090835
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.